Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

Background Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer
mortality but may increase mortality from other causes. Information regarding treatment …

Breast cancer is the leading cause of death from cancer in women worldwide, and the
second most common cause of death from cancer in women in the United States. Risk …

PURPOSE To update key recommendations of the American Society of Clinical
Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) …

Abstract Background The 16th St. Gallen International Breast Cancer Conference 2019 in
Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies …

Importance Statistically significant overall survival (OS) benefits of CDK4 and CDK6
inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 …

Purpose.—To update key recommendations of the American Society of Clinical
Oncology/College of American Pathologists estrogen receptor (ER) and progesterone …

The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …

Anti-estrogen therapy is a key component of the treatment of both early and advanced-stage
hormone receptor (HR)-positive breast cancer. This review discusses the recent emergence …

PURPOSE To develop recommendations concerning the management of male breast
cancer. METHODS ASCO convened an Expert Panel to develop recommendations based …